The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

Icatibant 30 mg solution for injection in pre-filled syringe

Fresenius Kabi Deutschland GmbHPA2059/075/001

Main Information

Trade NameIcatibant 30 mg solution for injection in pre-filled syringe
Active SubstancesIcatibant Acetate
Dosage FormSolution for injection in pre-filled syringe
Licence HolderFresenius Kabi Deutschland GmbH
Licence NumberPA2059/075/001

Group Information

ATC CodeB06AC02 icatibant


License statusAuthorised
Licence Issued11/03/2022
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of LicenceMedicinal product subject to restricted medical prescription (See Annex I: Summary of Product Characteristics, section 4.2)
Marketing StatusUnknown


Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back